A prospective, open-label, non-comparative study of ambrisentan with anti-fibrotic agent combination therapy in the treatment of diffuse systemic sclerosis.
Annemarie SchorpionMax SheninRobin NeubauerChris T DerkPublished in: BMC rheumatology (2018)
Clinicaltrials.gov, NCT01093885; March 2010.